Meta-analysis: Colchicine reduces new cardiovascular events in patients with coronary artery disease

Meta-analysis Evaluating the Utility of Colchicine in Secondary Prevention of Coronary Artery Disease – The American Journal of Cardiology (link to abstract – $ for full-text)

Commentary: Colchicine use proven beneficial for patients with coronary artery disease, according to new meta-analysis – Cardiovascular Business

Related randomized trials: Colchicine in patients with chronic coronary disease (study and commentaries) AND Low-Dose Colchicine Improves Outcomes after Myocardial Infarction (study and commentaries) AND Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) (study and commentary)

Commentary on Twitter

Meta-analysis Evaluating the Utility of Colchicine in Secondary Prevention of Coronary Artery Disease https://t.co/EbMATgpXn4
?Major adverse CV events 35%
?Risk of MI 27%
?Coronary revasc 39%
?Stroke 53% (0.47, CI 0.28-0.81)
?No impact on CV mortality@mencardio #colchicine

— Lempira Guevara Matheus (@Lguevaramath) October 31, 2020